Jim Cramer Says “I like Cencora A Lot” But Notes “Cardinal Health’s Got Them All Beat”

Cencora, Inc. (NYSE:COR) is one of the stocks Jim Cramer recently discussed. During the lightning round, a caller inquired about Cramer’s thoughts on the stock, and he commented:

“Okay, I like Cencora a lot. But I got to tell you, I think this Cardinal Health’s got them all beat. Jason Hollar is a visionary. I like that guy.”

Source: Unsplash

Cencora, Inc. (NYSE:COR) distributes pharmaceuticals, vaccines, plasma products, and healthcare supplies. The company also provides supports clinical trials, specialty distribution, animal health products, and biopharmaceutical transportation. During the May 14 episode, Cramer mentioned the stock and said:

“These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they’re some of the best performers out there, and they’ve done great this year, as is pretty much always the case. And yet, doesn’t it always feel like the drug distributors are just one bad day away from falling apart… Cencora… knocked it out of the park when they reported last Wednesday… Posted a slight top line miss but monster 31 cent earnings beat off of $4 [and] 11 cent basis.

Even better, just like Cardinal, management raised their full-year earnings forecast substantially. Cencora has raised its 2025 earnings guidance multiple times since originally issuing it in November. That’s what you really want if you’re a growth manager. The stock jumped 4.7% last Wednesday in response to the report, setting an all-time high of $309 and change before settling a little bit below that level…

The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what’s known as the Most-Favored-Nation pricing for Medicare…

As a result, all the drug distributors are either flat or slightly lower this week… so that’s the conundrum with these middlemen, Cardinal, Cencora, and McKesson are all doing incredibly well, but like I said before, there always seems to be a threat that they could be regulated out of existence.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.